British Gynaecological Cancer Society recommendations for evidence based, population data derived quality performance indicators for ovarian cancer
Abstract
Ovarian cancer survival in the UK lags behind comparable countries. Results from the ongoing National Ovarian Cancer Audit feasibility pilot (OCAFP) show that approximately 1 in 4 women with advanced ovarian cancer (Stage 2, 3, 4 and unstaged cancer) do not receive any anticancer treatment and only 51% in England receive international standard of care treatment, i.e., the combination of surgery and chemotherapy. The audit has also demonstrated wide variation in the percentage of women receiving anticancer treatment for advanced ovarian cancer, be it surgery or chemotherapy across the 19 geographical regions for organisation of cancer delivery (Cancer Alliances). Receipt of treatment also correlates with survival: 5 year Cancer survival varies from 28.6% to 49.6% across England. Here, we take a systems wide approach encompassing both diagnostic pathways and cancer treatment, derived from the whole cohort of women with ovarian cancer to set out recommendations and quality performance indicators (QPI). A multidisciplinary panel established by the British Gynaecological Cancer Society carefully identified QPI against criteria: metrics selected were those easily evaluable nationally using routinely available data and where there was a clear evidence base to support interventions. These QPI will be valuable to other taxpayer funded systems with national data collection mechanisms and are to our knowledge the only population level data derived standards in ovarian cancer. We also identify interventions for Best practice and Research recommendations.
Author
Sundar, Sudha
Nordin, Andy
Morrison, Jo
Wood, Nick
Ghaem-Maghami, Sadaf
Nieto, Jo
Phillips, Andrew
Butler, John
Burton, Kevin
Gornall, Rob
Dobbs, Stephen
Glasspool, Rosalind
Peevor, Richard
Ledermann, Jonathan
McNeish, Iain
Ratnavelu, Nithya
Duncan, Tim
Frost, Jonathan
Lim, Kenneth
Michael, Agnieszka
Brockbank, Elly
Gajjar, Ketankumar
Taylor, Alexandra
Bowen, Rebecca
Andreou, Adrian
Ganesan, Raji
Nicum, Shibani
Edmondson, Richard
Clayton, Richard
Balega, Janos
Rolland, Phil
Maxwell, Hilary
Fotopoulou, Christina
Nordin, Andy
Morrison, Jo
Wood, Nick
Ghaem-Maghami, Sadaf
Nieto, Jo
Phillips, Andrew
Butler, John
Burton, Kevin
Gornall, Rob
Dobbs, Stephen
Glasspool, Rosalind
Peevor, Richard
Ledermann, Jonathan
McNeish, Iain
Ratnavelu, Nithya
Duncan, Tim
Frost, Jonathan
Lim, Kenneth
Michael, Agnieszka
Brockbank, Elly
Gajjar, Ketankumar
Taylor, Alexandra
Bowen, Rebecca
Andreou, Adrian
Ganesan, Raji
Nicum, Shibani
Edmondson, Richard
Clayton, Richard
Balega, Janos
Rolland, Phil
Maxwell, Hilary
Fotopoulou, Christina
Citations
Altmetric:
Date
2023-01-04
Type
Article
Subject
Oncology. Pathology., Gynaecology
Collections
Citation
Sundar S, Nordin A, Morrison J, Wood N, Ghaem-Maghami S, Nieto J, Phillips A, Butler J, Burton K, Gornall R, Dobbs S, Glasspool R, Peevor R, Ledermann J, McNeish I, Ratnavelu N, Duncan T, Frost J, Lim K, Michael A, Brockbank E, Gajjar K, Taylor A, Bowen R, Andreou A, Ganesan R, Nicum S, Edmondson R, Clayton R, Balega J, Rolland P, Maxwell H, Fotopoulou C. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. Cancers (Basel). 2023 Jan 4;15(2):337. doi: 10.3390/cancers15020337
Journal / Source Title
Cancers
DOI
10.3390/cancers15020337
PMID
36672287
Publisher
MDPI